Revvity, Inc. (NYSE: RVTY), today announced that Sophie Vandebroek and Michael Klobuchar have been elected to its board of directors, effective February 1, 2024.

“I am pleased to welcome Michael Klobuchar and Sophie Vandebroek to Revvity’s board and look forward to their contributions as we execute on our strategic vision,” said Alexis Michas, non-executive chairman of the board. “Sophie brings deep acumen in AI, business processes, sustainability, and cybersecurity, along with academic advisory experience and leadership in global organizations. The board will benefit from her long track record of innovation and managing balanced research and development portfolios at large, diverse and inclusive organizations. Mike joins our board with a wealth of experience in developing and implementing strategic and operational initiatives for complex global enterprises. His depth and breadth of expertise across technical, operational, financial roles — and his deep commitment to scientific innovation — will provide the board with valuable insights to help propel Revvity forward.”

“I would also like to thank Dr. Sylvie Gregoire for her guidance serving on Revvity’s board since 2015, as she has decided not to stand for re-election after she finishes her current term at our annual shareholder meeting in April,” said Michas.

Dr. Vandebroek is the founder and owner of Strategic Vision Ventures, an innovation consulting firm. Previously, she was Massachusetts Institute of Technology’s Inaugural School of Engineering Visiting Scholar. Until 2019 she was Vice President of Emerging Technology Partnerships at IBM. Dr. Vandebroek also served as the Chief Operating Officer of IBM Research. Prior to joining IBM, she was Chief Technology Officer and President of the Xerox Innovation Group. Dr. Vandebroek led Xerox’s global laboratories, including PARC, Inc., where she was Chair of the board for eight years. Earlier in her career, Dr. Vandebroek was Xerox’s Chief Engineer and prior to that, VP of Xerox’s Canadian Research Center.

She is also a member of the Board of Directors of IDEXX Laboratories (IDXX), Inari Agriculture, and Wolters Kluwer N.V. Previously Dr. Vandebroek served on the Board of Directors of Analogic and Nypro Corporation. She holds 14 US patents and is a Fellow of the Institute of Electrical & Electronics Engineers (IEEE) and a Fellow of the Belgian-American Educational Foundation. Dr. Vandebroek holds a bachelor’s and master’s degree in electro-mechanical engineering from KU Leuven, Leuven, Belgium, and a Ph.D in electrical engineering from Cornell University.

Mr. Klobuchar is Executive Vice President and Chief Strategy Officer at Merck & Co. Inc. He is a member of Merck’s Executive Committee, and has served in his current role since 2021, overseeing the leadership, conception, planning and execution of strategies to achieve Merck’s vision, mission and business objectives. He is also responsible for setting and executing the company’s global business development and M&A strategies as well as leading the digital, data and IT infrastructure and cybersecurity strategies. Mr. Klobuchar prioritizes and pursues enterprise investment opportunities that modernize and expand the company’s innovation pipeline and technology portfolio across discovery, development, manufacturing and commercial. He has guided the company through more than $25B in M&A activity over the last three years.

Since joining Merck in 1998, Mr. Klobuchar has held positions of increasing responsibility in research, manufacturing, commercial planning, finance and strategy. Following the merger of Merck and Shering-Plough, he led key elements in the integration of the companies’ research operations. From 2019 to 2021, Mr. Klobuchar was Senior Vice President, CFO and Head of Portfolio and Alliance Management for Merck Research Laboratories, the company’s $13B research and development organization. Mr. Klobuchar holds an MBA from Villanova University, a master’s degree in chemical engineering from Rutgers University and a bachelor’s degree from Purdue University.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2022 revenue of more than $3 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240125165583/en/